---
title: Agilent Technologies (A) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/a
ticker: A
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Diagnostics & Research
---
# Agilent Technologies (A)

Agilent Technologies (A) closed at $172.97 on Oct 16, 2026, overvalued by 118% vs its model value of $79.20 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $172.97 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $79.20 |
| Price vs model | overvalued by 118% vs model |
| Range of that model | $54.60 – $145.92 |
| Market value | $48.8B |
| P/E (fiscal 2025) | 37.8 |
| Net margin (fiscal 2025) | 18.8% |
| Free cash flow (fiscal 2025) | $1.2B |
| Dividend yield (trailing twelve months) | 0.59% |
| Beta | 1.21 |
| Cost of capital (WACC) | 9.47% |
| Business classification | Mature & Stable (Low/slowing growth (~1% recent), Moderate margins (19% net margin), Highly cyclical earnings) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Near 52-week highs | #43 | −1.5% | https://sweetvaluelab.com/lists/near-52-week-highs |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 0.59% |
| Dividends per share, last 12 months | $1.02 |
| Dividends / free cash flow (fiscal 2025) | 24.5% |
| Raised | 13+ years in a row |
| Growth over 5 years | 5.6% a year |
| Latest payment | $0.255, ex-date Oct 6, 2026, paid Oct 28, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| To Oct 4, 2021 | $0.78 |
| To Oct 3, 2022 | $0.84 |
| To Oct 2, 2023 | $0.90 |
| To Oct 1, 2024 | $0.94 |
| To Sep 30, 2025 | $0.99 |
| Trailing twelve months (to Oct 6, 2026) | $1.02 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $79.20 | $54.60 | $145.92 |
| DCF · Perpetuity growth · 10y | cross check | $84.73 | $59.85 | $151.01 |
| DCF · EBITDA exit · 5y | cross check | $165.51 | $130.62 | $206.19 |
| DCF · EBITDA exit · 10y | cross check | $153.93 | $115.51 | $204.01 |
| P/E · peers | cross check | $178.67 | $137.46 | $212.22 |
| P/E · own history | cross check | $170.04 | $153.98 | $181.50 |
| PEG | sanity check | $93.61 | $93.61 | $93.61 |
| EV/EBITDA · peers | cross check | $164.32 | $119.06 | $181.12 |
| EV/Revenue · peers | cross check | $160.44 | $123.14 | $195.23 |
| Earnings power value | cross check | $22.44 | $18.62 | $27.69 |
| Dividend discount | cross check | $18.68 | $13.23 | $29.01 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 1 open-market sale ($95,971.8); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Sep 8, 2026 | Boehnlein Glenn S | Director | Grant / award | 817 | $119,976.5 |
| Sep 4, 2026 | Dolsten Mikael | Director | Open-market sell | 634 | $95,971.8 |
| Jun 26, 2026 | KIRKWOOD JONAH PREVOST | Senior Vice President | Tax withholding | 30 | $4,080.3 |
| Jun 3, 2026 | MCDONNELL PADRAIG | President and CEO | Tax withholding | 418 | $57,433.2 |
| May 29, 2026 | Dolsten Mikael | Director | Open-market sell | 1,600 | $216,672 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Sep 8, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1090872/000119312526384426/a-20260902.htm |
| Sep 1, 2026 | S-4 | Merger registration | https://www.sec.gov/Archives/edgar/data/1090872/000119312526378642/d110037ds4.htm |
| Sep 1, 2026 | S-3ASR | Shelf registration (automatic) | https://www.sec.gov/Archives/edgar/data/1090872/000119312526378628/d109384ds3asr.htm |
| Sep 1, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1090872/000109087226000064/a-20260731.htm |
| Aug 26, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1090872/000109087226000062/a-20260826.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| William Von Mueffling | 2026-06-30 | 126,437 | $16.8M |
| Bridgewater | 2026-06-30 | 22,889 | $3.0M |
| Greenhaven | 2026-06-30 | 10,700 | $1.4M |

3 tracked managers in all.

## About

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and mic…

---

Source: https://sweetvaluelab.com/stocks/a (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.